Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for indapamide

  1. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  2. Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

    In development [GID-TA11662] Expected publication date: 17 December 2025

    Technology appraisal guidance
    In development

  3. Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]

    In development [GID-TA11454] Expected publication date: 17 December 2025

    Technology appraisal guidance
    In development

  4. Hypertension in adults. Patient decision aid on how do I control my blood pressure? Lifestyle options and choice of medicines

    example, amlodipine, felodipine and lacidipine). A common example is indapamide. Table 2. What medicines could I try to control my blood...

  5. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

    NICE guideline
    Last updated
    21 November 2023
    View recommendations

    Sections for NG136